[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.207.136.184. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 392
Citations 0
Correction
January 2019

Missing Conflict of Interest Disclosure

JAMA Oncol. 2019;5(1):122. doi:10.1001/jamaoncol.2018.5678

In a number of articles published in JAMA Oncology,1-5 conflict of interest disclosures were not reported accurately by José Baselga, MD, PhD. Dr Baselga has written a Letter to the journal6 explaining this inconsistent reporting of potential conflict of interest disclosures. All articles have been corrected online.

References
1.
Ptashkin  RN, Mandelker  DL, Coombs  CC,  et al.  Prevalence of clonal hematopoiesis mutations in tumor-only clinical genomic profiling of solid tumors  [published online June 5, 2018].  JAMA Oncol. doi:10.1001/jamaoncol.2018.2297PubMedGoogle Scholar
2.
Diamond  EL, Subbiah  V, Lockhart  AC,  et al.  Vemurafenib for BRAF V600-mutant Erdheim-Chester disease and Langerhans cell histiocytosis: analysis of data from the histology-independent, phase 2, open-label VE-BASKET study.  JAMA Oncol. 2018;4(3):384-388. doi:10.1001/jamaoncol.2017.5029PubMedGoogle ScholarCrossref
3.
Fumagalli  D, Venet  D, Ignatiadis  M,  et al.  RNA sequencing to predict response to neoadjuvant anti-HER2 therapy: a secondary analysis of the NeoALTTO randomized clinical trial.  JAMA Oncol. 2016;3(2):227-234. doi:10.1001/jamaoncol.2016.3824PubMedGoogle ScholarCrossref
4.
Chandarlapaty  S, Chen  D, He  W,  et al.  Prevalence of ESR1 mutations in cell-free DNA and outcomes in metastatic breast cancer: a secondary analysis of the BOLERO-2 Clinical Trial.  JAMA Oncol. 2016;2(10):1310-1315. doi:10.1001/jamaoncol.2016.1279PubMedGoogle ScholarCrossref
5.
Salgado  R, Denkert  C, Campbell  C,  et al.  Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab: a secondary analysis of the NeoALTTO trial.  JAMA Oncol. 2015;1(4):448-454. doi:10.1001/jamaoncol.2015.0830PubMedGoogle ScholarCrossref
6.
Baselga  J.  Failure to accurately disclose conflicts of interest in articles published in JAMA Oncology  [published online October 26, 2018].  JAMA Oncol. doi:10.1001/jamaoncol.2018.5674PubMedGoogle Scholar
×